A phase II trial of dose-dense (biweekly) paclitaxel plus carboplatin as neoadjuvant chemotherapy for operable breast cancer

The aim of the present study is to investigate the efficacy and safety of dose-dense (biweekly) carboplatin and paclitaxel as a neoadjuvant treatment for operable breast cancer. Patients with previously untreated breast cancer (stages Ic–III) were treated with four cycles of paclitaxel (175 mg/m 2 ,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast cancer research and treatment 2016-02, Vol.156 (1), p.117-124
Hauptverfasser:	Zhu, T., Liu, C. L., Zhang, Y. F., Liu, Y. H., Xu, F. P., Zu, J., Zhang, G. C., Li, X. R., Liao, N., Wang, K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvant chemotherapy Adult Aged Antineoplastic agents Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Cancer research Cancer therapies Carboplatin - administration & dosage Carboplatin - adverse effects Carboplatin - therapeutic use Care and treatment Chemotherapy Clinical Trial Clinical trials Drug Administration Schedule Female Humans Medicine Medicine & Public Health Middle Aged Neoadjuvant Therapy - methods Oncology Paclitaxel - administration & dosage Paclitaxel - adverse effects Product development Receptor, ErbB-2 - genetics Studies Survival Analysis Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!